z-logo
Premium
Polyribonucleotides induce nitric oxide production by human monocyte‐derived macrophages
Author(s) -
Snell Julie C.,
Chernyshev Olga,
Gilbert Daniel L.,
Colton Carol A.
Publication year - 1997
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1002/jlb.62.3.369
Subject(s) - nitric oxide , biology , monocyte , macrophage , microbiology and biotechnology , production (economics) , biochemistry , immunology , in vitro , endocrinology , macroeconomics , economics
Cytokine‐mediated activation of inducible nitric oxide synthase (iNOS) in monocytes or macrophages is species specific. In contrast to rat or mouse, human macrophages do not produce measurable levels of nitric oxide (NO) when induced by inflammatory mediators. Exposure to noncytokine mediators such as tumor cells or viruses, however, has recently been shown to activate human iNOS. NO production in response to these mediators is much lower than that seen for rat or mouse cells and often requires several days of stimulation. We have found that the synthetic, double‐stranded polyribonucleotide polyinosinic‐polycytidilic acid (Poly I:C), commonly used to mimic viral exposure, activated iNOS in human monocyte‐derived macrophages (MDM). The production of NO, measured by nitrite accumulation, was detected after 24 h of stimulation with Poly I:C. The single‐stranded polyribonucleotide Poly I, but not Poly C, also increased NO production. Nitrite production was enhanced when the MDM were primed (pretreated) with γ or α interferon or other immune mediators such as IL‐4 and was reduced by the iNOS inhibitor, N‐methyl‐L‐arginine (L‐NMMA). The use of Poly I:C to initiate NO production in human macrophages provides a useful tool to study the differences between the commonly used animal models and human cells and may provide insight into the pathophysiological significance of these differences. J. Leukoc. Biol. 62: 369–373; 1997.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here